The Howard Hughes Medical Institute announced that Stanford University researcher Howard Chang has been appointed to a six-year term as part of the inaugural class of Howard Hughes Medical Institute Early Career Scientists.
Chang, an associate professor of dermatology, will receive $1.5 million over six years to support his research into the function of long, non-coding RNAs, according to HHMI.
Traversa Therapeutics has appointed two new members to its scientific advisory board.
Joining the SAB are William Kaelin, a professor of medicine at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, and Yitzhak Tor, a professor of chemistry and biochemistry at the University of California, San Diego.